Intestinal lipid handling: Evidence and implication of insulin signaling abnormalities in human obese subjects

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 3, 2014, Pages 644-653

  Veilleux, Alain ^a   Grenier, Émilie ^a   Marceau, Picard ^b   Carpentier, André C ^c   Richard, Denis ^d   Levy, Emile ^a,e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Diabetes mellitus, type 2; Dyslipidemias; Inflammation; Intestines; Oxidative stress

Indexed keywords

DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; INFLAMMATION; INTESTINES; OXIDATIVE STRESS;

ADULT; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARRIER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DUODENUM; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTESTINES; LIPOGENESIS; LIVER; MALE; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROPROTEIN CONVERTASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SERINE ENDOPEPTIDASES; YOUNG ADULT;

EID: 84894524906     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302993     Document Type: Article

References (58)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581
2. Taskinen MR. Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia. 2003;46:733-749
3. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, Nakamura SI, Yasue H. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation. 2000;102:670-676
4. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, Schaefer EJ. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: Results from the Framingham Heart Study. Atherosclerosis. 2001;154:229-236
5. Karpe F, Taskinen MR, Nieminen MS, Frick MH, Kesäniemi YA, Pasternack A, Hamsten A, Syvänne M. Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. Atherosclerosis. 2001;157:181-187
6. Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, Lewis GF, Adeli K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem. 2002;277:31646-31655
7. Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: Increased atherogenicity for the metabolic syndrome. Atherosclerosis. 2007;190:282-290
8. Zoltowska M, Ziv E, Delvin E, Sinnett D, Kalman R, Garofalo C, Seidman E, Levy E. Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: A model of insulin resistance and type 2 diabetes. Diabetes. 2003;52:2539-2545
9. Levy E, Sinnett D, Thibault L, Nguyen TD, Delvin E, Ménard D. Insulin modulation of newly synthesized apolipoproteins B-100 and B-48 in human fetal intestine: Gene expression and mRNA editing are not involved. FEBS Lett. 1996;393:253-258
10. Levy E, Spahis S, Ziv E, Marette A, Elchebly M, Lambert M, Delvin E. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: Impact of dietary n-3 fatty acids. Diabetologia. 2006;49:1937-1945
11. Adeli K, Lewis GF. Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol. 2008;19:221-228
12. Qin B, Qiu W, Avramoglu RK, Adeli K. Tumor necrosis factor-Alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes. 2007;56:450-461
13. Lewis GF, Naples M, Uffelman K, Leung N, Szeto L, Adeli K. Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: Studies in insulin-resistant and insulin-sensitized Syrian golden hamsters. Endocrinology. 2004;145:5006-5012
14. Lewis GF, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: Studies in the fructose-fed Syrian golden hamster. Endocrinology. 2005;146:247-255
15. Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: Evidence for activation of protein tyrosine phosphatase-1B, extracellular signalrelated kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes. 2006;55:1316-1326
16. Levy E, Lalonde G, Delvin E, Elchebly M, Précourt LP, Seidah NG, Spahis S, Rabasa-Lhoret R, Ziv E. Intestinal and hepatic cholesterol carriers in diabetic Psammomys obesus. Endocrinology. 2010;151:958-970
17. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol. 2006;26:1357-1363
18. Duez H, Pavlic M, Lewis GF. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atheroscler Suppl. 2008;9:33-38
19. Couture P, Tremblay AJ, Kelly I, Lemelin V, Droit A, Lamarche B. Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance. J Lipid Res. 2014;55:128-137
20. Field FJ, Watt K, Mathur SN. Origins of intestinal ABCA1-mediated HDL-cholesterol. J Lipid Res. 2008;49:2605-2619
21. Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier É, Emonnot L, Yara S, Couture P, Beaulieu JF, Ménard D, Seidah NG, Elchebly M. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013;227:297-306
22. Niesen M, Bedi M, Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys. 2008;470:111-115
23. Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med. 2010;77:511-523
24. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: Clinical and pathogenic data. Liver Int. 2009;29(suppl 2):13-25
25. Stumvoll M, Goldstein BJ, van Haeften TW. Pathogenesis of type 2 diabetes. Endocr Res. 2007;32:19-37
26. Serhan MF, Kreydiyyeh SI. Insulin targets the Na(+)/K(+) ATPase in enterocytes via PI3K, PKC, and MAPKS. J Recept Signal Transduct Res. 2011;31:299-306
27. Levy E, Thibault L, Ménard D. Intestinal lipids and lipoproteins in the human fetus: Modulation by epidermal growth factor. J Lipid Res. 1992;33:1607-1617
28. Loirdighi N, Ménard D, Levy E. Insulin decreases chylomicron production in human fetal small intestine. Biochim Biophys Acta. 1992;1175:100-106
29. Olsen WA, Rosenberg IH. Intestinal transport of sugars and amino acids in diabetic rats. J Clin Invest. 1970;49:96-105
30. Hopfer U. Diabetes mellitus: Changes in the transport properties of isolated intestinal microvillous membranes. Proc Natl Acad Sci U S A. 1975;72:2027-2031
31. Brasitus TA, Dudeja PK. Correction of abnormal lipid fluidity and composition of rat ileal microvillus membranes in chronic streptozotocin-induced diabetes by insulin therapy. J Biol Chem. 1985;260:12405-12409
32. Feingold KR, Wiley MH, MacRae G, Moser AH, Lear SR, Siperstein MD. The effect of diabetes mellitus on sterol synthesis in the intact rat. Diabetes. 1982;31(5 Pt 1):388-395
33. Rehfeld JF. A centenary of gastrointestinal endocrinology. Horm Metab Res. 2004;36:735-741
34. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: Mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89:2608-2615
35. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-242
36. Huff MW. Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis. Can J Clin Pharmacol. 2003;10(suppl A):26A-32A.
37. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb. 2009;16:145-154
38. Yu KC, Cooper AD. Postprandial lipoproteins and atherosclerosis. Front Biosci. 2001;6:D332-D354
39. Wilhelm MG, Cooper AD. Induction of atherosclerosis by human chylomicron remnants: A hypothesis. J Atheroscler Thromb. 2003;10:132-139
40. Marcil V, Delvin E, Sané AT, Tremblay A, Levy E. Oxidative stress influences cholesterol efflux in THP-1 macrophages: Role of ATP-binding cassette A1 and nuclear factors. Cardiovasc Res. 2006;72:473-482
41. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: Prevention by cilostazol. Circulation. 2004;109:1022-1028
42. Dhote V, Joharapurkar A, Kshirsagar S, Dhanesha N, Patel V, Patel A, Raval S, Jain M. Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats. Clin Exp Pharmacol Physiol. 2011;38:338-344
43. van Hees AM, Jans A, Hul GB, Roche HM, Saris WH, Blaak EE. Skeletal muscle fatty acid handling in insulin resistant men. Obesity (Silver Spring). 2011;19:1350-1359
44. Murphy MP, Holmgren A, Larsson NG, Halliwell B, Chang CJ, Kalyanaraman B, Rhee SG, Thornalley PJ, Partridge L, Gems D, Nyström T, Belousov V, Schumacker PT, Winterbourn CC. Unraveling the biological roles of reactive oxygen species. Cell Metab. 2011;13:361-366
45. Martínez JA. Mitochondrial oxidative stress and inflammation: An slalom to obesity and insulin resistance. J Physiol Biochem. 2006;62:303-306
46. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30:49-59
47. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem. 1995;270:933-943
48. Nakao S, Ogtata Y, Shimizu E, Yamazaki M, Furuyama S, Sugiya H. Tumor necrosis factor alpha (TNF-Alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. Mol Cell Biochem. 2002;238:11-18
49. Paik J, Lee JY, Hwang D. Signaling pathways for TNFa-induced COX-2 expression: Mediation through MAP kinases and NFkB, and inhibition by certain nonsteroidal anti-inflammatory drugs. Adv Exp Med Biol. 2002;507:503-508
50. Nunn AV, Bell JD, Guy GW. Lifestyle-induced metabolic inflexibility and accelerated ageing syndrome: Insulin resistance, friend or foe? Nutr Metab (Lond). 2009;6:16
51. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: Role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest. 2003;33:1051-1069
52. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999;103:1191-1199
53. Lopez D. PCSK9: An enigmatic protease. Biochim Biophys Acta. 2008;1781:184-191
54. Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T, Prat A, Seidah NG, Chretien M, Scott FW. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2010;584:701-706
55. Leblond F, Seidah NG, Précourt LP, Delvin E, Dominguez M, Levy E. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2009;296:G805-G815
56. Levy E, Lalonde G, Delvin E, Elchebly M, Précourt LP, Seidah NG, Spahis S, Rabasa-Lhoret R, Ziv E. Intestinal and hepatic cholesterol carriers in diabetic Psammomys obesus. Endocrinology. 2010;151:958-970
57. Brouwers MC, Troutt JS, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, Schaper NC, Schalkwijk CG, Konrad RJ, Stehouwer CD. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Atherosclerosis. 2011;217:263-267
58. Herbert B, Patel D, Waddington SN, Eden ER, McAleenan A, Sun XM, Soutar AK. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol. 2010;30:1333-1339